J&J, Pfizer, Merck again lead pharma in Fortune 500
Johnson & Johnson, Pfizer and Merck & Co. continue to live up to their big pharma titles, having again secured the top three spots amongst drug companies on the recent Fortune 500 list.
On the list, J&J was ranked 37, Pfizer 57, and Merck 78. Eight other drugmakers also made the list: Abbvie at 110; Gilead Sciences at 116; Eli Lilly at 129; Amgen at 130; Bristol-Myers Squibb at 145; Celgene at 224; Biogen at 245; and Regeneron Pharmaceuticals at 473.
Fortune ranks companies based on yearly revenues. Companies must file some kind of annual financial document with a government agency and be incorporated in the U.S. — meaning large players overseas like Novartis and Roche aren’t eligible.
